Global Nucleic Acid Therapeutic Market Research Report 2025

Publication ID:

PB505257930

Publication Date:

May 30, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Nucleic Acid Therapeutic was valued at US$ 12900 million in the year 2024 and is projected to reach a revised size of US$ 16590 million by 2031, growing at a CAGR of 3.7% during the forecast period.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Therapeutic.
The Nucleic Acid Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acid Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Nucleic Acid Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Therapeutic Market Perspective (2020-2031)
2.2 Global Nucleic Acid Therapeutic Growth Trends by Region
2.2.1 Global Nucleic Acid Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Nucleic Acid Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 Nucleic Acid Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 Nucleic Acid Therapeutic Market Dynamics
2.3.1 Nucleic Acid Therapeutic Industry Trends
2.3.2 Nucleic Acid Therapeutic Market Drivers
2.3.3 Nucleic Acid Therapeutic Market Challenges
2.3.4 Nucleic Acid Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Therapeutic Players by Revenue
3.1.1 Global Top Nucleic Acid Therapeutic Players by Revenue (2020-2025)
3.1.2 Global Nucleic Acid Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global Nucleic Acid Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Nucleic Acid Therapeutic Revenue
3.4 Global Nucleic Acid Therapeutic Market Concentration Ratio
3.4.1 Global Nucleic Acid Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Therapeutic Revenue in 2024
3.5 Global Key Players of Nucleic Acid Therapeutic Head office and Area Served
3.6 Global Key Players of Nucleic Acid Therapeutic, Product and Application
3.7 Global Key Players of Nucleic Acid Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Therapeutic Breakdown Data by Type
4.1 Global Nucleic Acid Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global Nucleic Acid Therapeutic Forecasted Market Size by Type (2026-2031)
5 Nucleic Acid Therapeutic Breakdown Data by Application
5.1 Global Nucleic Acid Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global Nucleic Acid Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Nucleic Acid Therapeutic Market Size (2020-2031)
6.2 North America Nucleic Acid Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Nucleic Acid Therapeutic Market Size by Country (2020-2025)
6.4 North America Nucleic Acid Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Therapeutic Market Size (2020-2031)
7.2 Europe Nucleic Acid Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Nucleic Acid Therapeutic Market Size by Country (2020-2025)
7.4 Europe Nucleic Acid Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific Nucleic Acid Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Nucleic Acid Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific Nucleic Acid Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Therapeutic Market Size (2020-2031)
9.2 Latin America Nucleic Acid Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Nucleic Acid Therapeutic Market Size by Country (2020-2025)
9.4 Latin America Nucleic Acid Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa Nucleic Acid Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Nucleic Acid Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa Nucleic Acid Therapeutic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid Therapeutic Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid Therapeutic Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid Therapeutic Introduction
11.3.4 Alnylam Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Nucleic Acid Therapeutic Introduction
11.4.4 Biogen Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Nucleic Acid Therapeutic Introduction
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Nucleic Acid Therapeutic Introduction
11.6.4 Sobi Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Nucleic Acid Therapeutic Introduction
11.7.4 Novartis Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Nucleic Acid Therapeutic Introduction
11.8.4 BioNTech Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Nucleic Acid Therapeutic Introduction
11.9.4 Pfizer Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Nucleic Acid Therapeutic Introduction
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Nucleic Acid Therapeutic Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Nucleic Acid Therapeutic Introduction
11.12.4 CureVac Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Nucleic Acid Therapeutic Introduction
11.13.4 Regulus Therapeutics Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Nucleic Acid Therapeutic Introduction
11.14.4 ProQR Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Nucleic Acid Therapeutic Introduction
11.15.4 Secarna Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Nucleic Acid Therapeutic Introduction
11.16.4 MiNA Therapeutics Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Nucleic Acid Therapeutic Introduction
11.17.4 Sylentis Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Nucleic Acid Therapeutic Introduction
11.18.4 Arrowhead Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Nucleic Acid Therapeutic Introduction
11.19.4 Silence Therapeutics Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Nucleic Acid Therapeutic Introduction
11.20.4 Dicerna Revenue in Nucleic Acid Therapeutic Business (2020-2025)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂